Advertisement
Canada markets open in 6 hours 17 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7328
    +0.0005 (+0.06%)
     

  • CRUDE OIL

    84.11
    +0.54 (+0.65%)
     

  • Bitcoin CAD

    87,730.78
    -24.30 (-0.03%)
     

  • CMC Crypto 200

    1,390.46
    -6.07 (-0.43%)
     

  • GOLD FUTURES

    2,352.20
    +9.70 (+0.41%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,762.00
    +194.50 (+1.11%)
     

  • VOLATILITY

    15.37
    0.00 (0.00%)
     

  • FTSE

    8,078.86
    0.00 (0.00%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Evoke Pharma, Inc.
·2 min read

SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, will participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 – 15, 2021.

Event:

H.C. Wainwright 23rd Annual Global Investment Conference

Format:

Corporate Presentation and One-on-One Meetings

Date:

Monday, September 13, 2021 (presentation)

Location:

Virtual

Time:

Available on-demand starting at 7:00 am ET to those attending the conference virtually

Investors participating in the conference who would like to schedule a one-on-one call with Evoke management may do so by contacting their H.C. Wainwright representative, or Christine Petraglia of The Ruth Group at cpetraglia@theruthgroup.com.

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

ADVERTISEMENT

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Follow GIMOTI on Facebook: https://www.facebook.com/Gimoti-metoclopramide-nasal-spray-104672345100289

Follow Evoke Pharma on Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724

Follow Evoke Pharma on LinkedIn: https://www.linkedin.com/company/evoke-pharma/

Investor Contact:
The Ruth Group
Christine Petraglia
Tel: 917-633-8980
cpetraglia@theruthgroup.com

Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
aparrish@theruthgroup.com